WO2023246847A1 - Peptide bloquant b2m-glun1, composition pharmaceutique et son utilisation - Google Patents
Peptide bloquant b2m-glun1, composition pharmaceutique et son utilisation Download PDFInfo
- Publication number
- WO2023246847A1 WO2023246847A1 PCT/CN2023/101626 CN2023101626W WO2023246847A1 WO 2023246847 A1 WO2023246847 A1 WO 2023246847A1 CN 2023101626 W CN2023101626 W CN 2023101626W WO 2023246847 A1 WO2023246847 A1 WO 2023246847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glun1
- human brain
- disease
- alzheimer
- down syndrome
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000000903 blocking effect Effects 0.000 title description 16
- 101710121995 Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 claims abstract description 69
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 claims abstract description 69
- 210000004556 brain Anatomy 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 230000004697 synapse damage Effects 0.000 claims abstract description 11
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims abstract description 10
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims abstract description 10
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims abstract description 10
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 208000024827 Alzheimer disease Diseases 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 80
- 241000699670 Mus sp. Species 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 102000001189 Cyclic Peptides Human genes 0.000 description 16
- 108010069514 Cyclic Peptides Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 210000001320 hippocampus Anatomy 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000005013 brain tissue Anatomy 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000000749 co-immunoprecipitation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 6
- 102000003678 AMPA Receptors Human genes 0.000 description 6
- 108090000078 AMPA Receptors Proteins 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 6
- 101000972832 Rattus norvegicus Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003531 protein hydrolysate Substances 0.000 description 6
- 210000002763 pyramidal cell Anatomy 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 101000972838 Homo sapiens Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000003956 synaptic plasticity Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 201000006347 Intellectual Disability Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011818 5xFAD mouse Methods 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000030979 Language Development disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- TWYVVGMYFLAQMU-UHFFFAOYSA-N gelgreen Chemical compound [I-].[I-].C1=C(N(C)C)C=C2[N+](CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]3=C4C=C(C=CC4=CC4=CC=C(C=C43)N(C)C)N(C)C)=C(C=C(C=C3)N(C)C)C3=CC2=C1 TWYVVGMYFLAQMU-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003650 pro-aging effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention belongs to the field of biomedicine and relates to B2M-GluN1 blocking peptide, its pharmaceutical composition and uses.
- Down syndrome also known as Trisomy 21, is one of the most common intellectual disabilities. About 1 in 800 newborns worldwide suffer from this disease. Patients with Down syndrome have one or part of chromosome 21. The increase in gene copy number on chromosome 21 leads to abnormal gene expression and ultimately causes symptoms of a variety of diseases, including developmental delay, intellectual disability, language delay, immune and endocrine systems. Abnormalities and defects in the bones, heart, and digestive system, among others. Intellectual retardation is the most prominent and serious symptom of Down syndrome. The vast majority of children have varying degrees of intellectual development disabilities. Most of the children have IQs of about 25 to 50 (normal people are above 90). It becomes more and more obvious with age, and language problems , memory, abstract thinking, etc. will be damaged.
- Alzheimer's disease is one of the most common neurodegenerative diseases in humans. According to the World Alzheimer's Disease 2018 Report, 50 million people worldwide were suffering from Alzheimer's disease in 2018. By 2050, this number will will increase to 152 million.
- the main pathological characteristics of the disease include amyloid deposition formed by the oligomerization of ⁇ -amyloid (A ⁇ ) produced by the cleavage of amyloid precursor protein (APP) in the brain, and abnormal phosphorylation of the intracellular microtubule-binding protein tau.
- a ⁇ ⁇ -amyloid
- APP amyloid precursor protein
- NFTs Neurofibrillary tangles
- Alzheimer's disease patients memory decline and cognitive impairment, and this decline worsens as the disease progresses, eventually leading to the loss of all memory and ability to take care of themselves until death.
- cognitive impairment the main clinical manifestations of Alzheimer's disease patients.
- this decline worsens as the disease progresses, eventually leading to the loss of all memory and ability to take care of themselves until death.
- GluN1 is a component subunit of the NMDA receptor. It is encoded by the human chromosome 9 gene. It contains 938 amino acids and is a three-transmembrane protein, including the N-terminal extracellular segment, C-terminal intracellular segment, transmembrane structure and cell structure. Extracellular loop.
- NMDA receptors are considered to be a potential pathogenic feature of a variety of neurological diseases, such as ischemic stroke, traumatic brain injury, Alzheimer's disease, epilepsy, mood disorders, and schizophrenia.
- NMDA receptors are diverse in terms of subunit composition, biophysical and pharmacological properties, interactions and subcellular localization. developing Subunit composition varies in different CNS regions during processes and disease states.
- NMDA receptors have always been a research hotspot and drug target in the field of neuropharmacology.
- interest in NMDA receptor modulators as therapeutic agents has also increased significantly. Therefore, these compounds will provide new tools to study the physiology of NMDA receptor signaling, thereby revealing new therapeutic opportunities.
- Memantine a drug currently approved by the FDA for the treatment of Alzheimer's disease, is a reversible blocker of NMDA glutamate receptors, but its mechanism and mode of action are completely different from those of the present invention.
- B2M ⁇ 2-microglobulin
- MHC-I Major histocompatibility complex I
- B2M protein exists in the form of soluble monomers, but under the influence of some pathological factors, B2M will aggregate and deposit. These pathological factors include aging, long-term renal dysfunction, and inflammation.
- B2M amyloid deposition is mainly found in bone and joint areas and eventually leads to severe arthritis, fractures and carpal tunnel syndrome.
- the levels of B2M in serum and plasma are increased in many disease states.
- B2M has a direct or indirect impact on the development of Down syndrome and Alzheimer's disease.
- the inventor discovered the role of B2M in the occurrence and development of Down syndrome.
- the inventor surprisingly found that the blocking peptide that hinders the binding of B2M and GluN1 has the potential to prevent and treat Down syndrome or The potential of drugs to treat cognitive impairment caused by Alzheimer's disease.
- the following invention is thereby provided:
- One aspect of the present invention relates to an isolated polypeptide, which is the polypeptide shown in SEQ ID NO: 8 or a truncated fragment of the polypeptide shown in SEQ ID NO: 8; preferably, the truncated fragment comprises SEQ ID NO: The polypeptide shown in 11.
- the isolated polypeptide is a polypeptide represented by any one of SEQ ID NO: 11 or SEQ ID NOs: 14-32.
- Another aspect of the invention relates to an isolated polynucleotide encoding an isolated polypeptide according to any one of the invention.
- Yet another aspect of the invention relates to a recombinant expression vector comprising an isolated polynucleotide of the invention.
- Yet another aspect of the invention relates to a transformed cell comprising the recombinant expression vector of the invention.
- Yet another aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising one or more (eg 2, 3, 4 or 5) isolated polypeptides according to any one of the invention.
- the pharmaceutical composition further contains one or more pharmaceutically acceptable excipients.
- Another aspect of the present invention relates to the use of the isolated polypeptide according to any one of the present invention for the treatment or prevention of Down syndrome, Alzheimer's disease, or the diagnosis caused by Down syndrome or Alzheimer's disease. Use in medicines that prevent damage.
- Another aspect of the present invention relates to the use of the isolated polypeptide according to any one of the present invention in the preparation of the following medicines: use:
- Drugs that reduce B2M levels in the human brain drugs that reduce amyloid precursor protein levels in the human brain, drugs that inhibit the binding of GluN1 to B2M in the human brain, or drugs that repair synaptic damage caused by increased B2M in the human brain.
- the isolated polypeptide according to any one of the present invention is used to treat or prevent Down syndrome, Alzheimer's disease, or cognitive impairment caused by Down syndrome or Alzheimer's disease.
- the isolated polypeptide according to any one of the present invention is used to reduce the level of B2M in the human brain, reduce the level of amyloid precursor protein in the human brain, inhibit the binding of GluN1 to B2M in the human brain, or repair B2M in the human brain. Increased synaptic damage caused.
- Yet another aspect of the present invention relates to a method for treating or preventing Down syndrome, Alzheimer's disease, or cognitive impairment caused by Down syndrome or Alzheimer's disease, comprising administering to a subject in need or with an effective amount of an isolated polypeptide of any one of the invention.
- Yet another aspect of the present invention relates to a method for reducing B2M levels in the human brain, reducing amyloid precursor protein levels in the human brain, inhibiting the binding of GluN1 to B2M in the human brain, or repairing synaptic damage caused by increased B2M in the human brain. , comprising the step of administering an effective amount of an isolated polypeptide of any one of the invention to a subject in need thereof.
- the method of treating or preventing Down syndrome, Alzheimer's disease, or cognitive impairment caused by Down syndrome or Alzheimer's disease or the method Methods for inhibiting the binding of GluN1 to B2M in the human brain or repairing synaptic damage caused by increased B2M in the human brain, wherein,
- the single dosage of the isolated polypeptide according to any one of the present invention is 0.1-100 mg per kilogram of body weight, preferably 5-50 mg or 5-15 mg per kilogram of body weight;
- it is administered every 3 days, every 4 days, every 5 days, every 6 days, every 10 days, every 1 week, every 2 weeks or every 3 weeks;
- the administration method is intravenous drip or intravenous injection.
- the present invention discovered for the first time that the expression of B2M in the brain tissue of patients with Down syndrome is significantly increased. Increased B2M will damage synaptic plasticity and cognitive function. Furthermore, the inventors found that there is a direct interaction between B2M and the extracellular segment of GluN1. Using a truncated GluN1 amino acid sequence as a blocking peptide can hinder the binding of B2M to GluN1 and inhibit the function of B2M from damaging NMDA receptors. In vivo experiments show that blocking The peptide can significantly inhibit the binding of B2M and GluN1 in the brain and enhance synaptic plasticity. This discovery provides a potential clinical treatment for Down syndrome Drug targets and new treatments based on these targets.
- amino acid sequence of GluN1 is shown in SEQ ID NO: 1.
- amino acid sequence (N-terminus to C-terminus) of rat GluN1 protein is as follows:
- amino acid sequence (N-terminus to C-terminus) of human GluN1 protein is as follows:
- the terms “isolated” or “isolated” refer to those obtained by artificial means from the natural state. If an "isolated" substance or ingredient occurs in nature, it may be that the natural environment in which it is located has changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the high purity of the same polynucleotide or polypeptide isolated from this natural state is called isolation. of.
- isolation a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the high purity of the same polynucleotide or polypeptide isolated from this natural state is called isolation. of.
- the term “isolated” or “isolated” does not exclude the admixture of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.
- an effective amount refers to an amount sufficient to obtain, at least in part, the desired effect.
- an effective amount to prevent a disease is an amount sufficient to prevent, prevent, or delay the occurrence of a disease (such as Down syndrome or Alzheimer's disease); treat a disease
- An effective amount is an amount sufficient to cure or at least partially prevent disease and its complications in a patient already suffering from the disease. Determining such effective amounts is well within the capabilities of those skilled in the art.
- the amount effective for therapeutic use will depend on the severity of the disease to be treated, the overall status of the patient's own immune system, the patient's general condition such as age, weight and gender, the manner in which the drug is administered, and other treatments administered concurrently etc.
- blocking peptide refers to a protein that competitively binds to B2M with the full-length GluN1 protein, thereby inhibiting B2M binding.
- the biological effects of GluN1 on synaptic plasticity impairment are not limited to GluN1 and fragments thereof.
- Figure 3B Immunoprecipitation of B2M and N-terminally deleted GluN1 using anti-HA antibodies.
- Figure 3D Immunoprecipitation of B2M and GluN1 extracellular cyclic peptides using anti-HA antibodies.
- Figure 4D The above three short peptides without overlapping sequences were pre-incubated with Ni-NTA Agarose in PBS solution for 8 hours at 4°C, and then hB2M protein was added and incubated at 4°C overnight. Western blot detection and analysis were performed the next day.
- Figure 5B NMDAR EPSC amplitude statistical graph.
- the hippocampus of 3-month-old C57BL/6 mice was stereotaxically injected with 1 ⁇ l (1 ⁇ g/ ⁇ l) GluN1-P2 truncated peptide or Non-sense peptide (the left and right brains of each mouse were controlled).
- the mice were brain-dissected.
- the brain slices were incubated with B2M protein (concentration 10 ⁇ g/ml) and ACSF for two hours respectively, and electrophysiological recording was performed after incubation.
- amyloid precursor protein encoded by chromosome 21 in the brain tissue of Down syndrome patients and Dp16 mice was significantly higher than that of the respective control groups.
- Rat GluN1 N-terminal extracellular segment deletion (100% homology to human GluN1 N-terminal extracellular segment deletion)
- Rat GluN1 extracellular cyclic peptide (100% homology with human GluN1 extracellular cyclic peptide)
- PEI cell transfection
- GluN1 is a three-transmembrane protein, including an N-terminal extracellular segment, a C-terminal intracellular segment, a transmembrane structure and an extracellular loop.
- B2M Interacts with both N-terminal deletion (GluN1-N terminal deletion-myc) ( Figure 3B) and C-terminal deletion GluN1 (GluN1-C terminal deletion-myc) ( Figure 3C).
- GluN1 with N-terminal deletion and C-terminus deletion contain a common extracellular cyclic peptide region.
- a co-immunoprecipitation experiment was performed on the GluN1 extracellular cyclic peptide fragment and B2M. The results showed that the GluN1 extracellular cyclic peptide fragment can interact with B2M ( Figure 3D).
- GluN1 truncated peptide can be used as a blocking peptide to prevent GluN1 from binding to B2M and prevent B2M. GluN1 acts to produce inhibition
- Rat GluN1-S2loop-L1 (100% homology to human GluN1-S2loop-L1)
- Rat GluN1-S2loop-L2 (100% homology to human GluN1-S2loop-L2)
- Rat GluN1-S2loop-L3 (100% homology to human GluN1-S2loop-L3)
- the GluN1-P2 short peptide can be used as a blocking peptide to prevent GluN1 from binding to B2M, making B2M unable to inhibit NMDA receptor function.
- Example 5 GluN1-P2 blocking peptide blocks the binding of B2M to GluN1, thereby reducing synaptic damage
- GluN1 is an essential subunit of NMDA receptors. Impairment of its function will severely damage synaptic plasticity. GluN1-P2 blocking peptide can prevent B2M from binding to GluN1. Therefore, it is necessary to study whether GluN1-P2 blocking peptide can prevent B2M from damaging NMDA. Receptor function in turn impairs excitatory synaptic function.
- the hippocampus of 6-month-old Dp16 mice and control WT mice were stereotaxically injected with 1 ⁇ l (1 ⁇ g/ ⁇ l) GluN1-P2 short peptide or Non-sense peptide (the left CA1 area of each mouse was injected with the GluN1-P2 short peptide, and the right Non-sense peptide) was injected into the lateral CA1 area, and electrophysiological recording was performed one day after injection. Record the NMDAR EPSCs of the Schaeffer collateral circuit in the hippocampus.
- the stimulating electrode is placed near the CA3 area to record the pyramidal cell current in the CA1 area. 5mM QX-314 is added to the electrode internal solution, and 50 ⁇ M PTX and 20 ⁇ M CNQX are added to the perfusion solution to block respectively.
- GABA A receptor and AMPA receptor ion channels, clamping voltage is +40mV.
- the hippocampus of 3-month-old C57BL/6 mice was stereotaxically injected with 1 ⁇ l (1 ⁇ g/ ⁇ l) GluN1-P2 truncated peptide or Non-sense peptide (the left and right brains of each mouse were controlled).
- the mice were brain-dissected.
- the brain slices were incubated with B2M protein (concentration 10 ⁇ g/ml) and ACSF for two hours respectively, and electrophysiological recording was performed after incubation. Record the NMDAR EPSC amplitude of the Schaeffer collateral loop in the hippocampus.
- the stimulating electrode is placed near the CA3 area to record the pyramidal cell current in the CA1 area.
- 5mM QX-314 is added to the electrode internal solution, and 50 ⁇ M PTX and 20 ⁇ M CNQX are added to the perfusate to block the current.
- the brain tissue was quickly removed and placed in ice-cold and oxygen-saturated artificial cerebrospinal fluid (ACSF), and then transferred to a vibrating microtome for coronal sectioning.
- the thickness of the brain slices was 400 ⁇ m.
- the brain slices were incubated in oxygen-saturated ACSF at 32°C for 1 hour, and then transferred to room temperature for 1 hour.
- the recording electrode was placed in the stratum radiatum of the CA1 area of the Schaffer collateral pathway, and the stimulating electrode was placed in the CA3 area.
- the stimulation intensity was 30% of the maximum amplitude of the excitatory postsynaptic potential (fEPSP).
- HFS high-frequency stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
L'invention concerne un médicament pour réduire le niveau de B2M dans le cerveau humain, un médicament pour réduire le niveau d'une protéine précurseur amyloïde dans le cerveau humain, un médicament pour inhiber la liaison de GluN1 et de B2M dans le cerveau humain, ou un médicament pour réparer les dommages synaptiques causés par l'augmentation de B2M dans le cerveau humain.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210722699.7 | 2022-06-24 | ||
CN202210722699.7A CN117327168A (zh) | 2022-06-24 | 2022-06-24 | B2M-GluN1封闭肽、其药物组合物及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023246847A1 true WO2023246847A1 (fr) | 2023-12-28 |
Family
ID=89290693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/101626 WO2023246847A1 (fr) | 2022-06-24 | 2023-06-21 | Peptide bloquant b2m-glun1, composition pharmaceutique et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117327168A (fr) |
WO (1) | WO2023246847A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628821A (zh) * | 2015-01-21 | 2015-05-20 | 徐州医学院 | 具有神经保护作用的肽及应用 |
US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
CN108473566A (zh) * | 2016-01-15 | 2018-08-31 | 伊莱利利公司 | 抗N3pGlu淀粉样蛋白β肽抗体及其用途 |
CN109646668A (zh) * | 2019-01-04 | 2019-04-19 | 厦门大学 | 一种多肽用于制备防治阿尔茨海默病药物的用途 |
CN110582511A (zh) * | 2017-04-20 | 2019-12-17 | 伊莱利利公司 | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 |
CN111320684A (zh) * | 2018-12-13 | 2020-06-23 | 中国科学院脑科学与智能技术卓越创新中心 | 人源N-甲基-D-天冬氨酸受体的GluN1/GluN2A四聚体的表达及其应用 |
-
2022
- 2022-06-24 CN CN202210722699.7A patent/CN117327168A/zh active Pending
-
2023
- 2023-06-21 WO PCT/CN2023/101626 patent/WO2023246847A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628821A (zh) * | 2015-01-21 | 2015-05-20 | 徐州医学院 | 具有神经保护作用的肽及应用 |
CN108473566A (zh) * | 2016-01-15 | 2018-08-31 | 伊莱利利公司 | 抗N3pGlu淀粉样蛋白β肽抗体及其用途 |
US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
CN110582511A (zh) * | 2017-04-20 | 2019-12-17 | 伊莱利利公司 | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 |
CN111320684A (zh) * | 2018-12-13 | 2020-06-23 | 中国科学院脑科学与智能技术卓越创新中心 | 人源N-甲基-D-天冬氨酸受体的GluN1/GluN2A四聚体的表达及其应用 |
CN109646668A (zh) * | 2019-01-04 | 2019-04-19 | 厦门大学 | 一种多肽用于制备防治阿尔茨海默病药物的用途 |
Non-Patent Citations (1)
Title |
---|
GAO YUE, HONG YUJUAN, HUANG LIHONG, ZHENG SHUANG, ZHANG HAIBIN, WANG SHIHUA, YAO YI, ZHAO YINI, ZHU LIN, XU QIANG, CHAI XUHUI, ZEN: "β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function", CELL, ELSEVIER, AMSTERDAM NL, vol. 186, no. 5, 1 March 2023 (2023-03-01), Amsterdam NL , pages 1026 - 1038.e20, XP093119702, ISSN: 0092-8674, DOI: 10.1016/j.cell.2023.01.021 * |
Also Published As
Publication number | Publication date |
---|---|
CN117327168A (zh) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4351896B2 (ja) | p38/JTV−1を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法 | |
CN107921085B (zh) | 用于治疗衰老相关病症的方法和组合物 | |
JP4855268B2 (ja) | アルツハイマー治療剤 | |
US9382313B2 (en) | Modulation of synaptic maintenance | |
JP2019530468A (ja) | 修飾されたリガンド依存性イオンチャネルおよび使用の方法 | |
EP2328917B1 (fr) | Facteur de viabilité neuronale et son utilisation | |
US20210268126A1 (en) | Treating spinal cord injury (sci) and brain injury using gsx1 | |
WO2023045662A1 (fr) | Application contre la dépression et l'anxiété d'un polypeptide et d'un complexe | |
Lu et al. | Targeting WWP1 ameliorates cardiac ischemic injury by suppressing KLF15-ubiquitination mediated myocardial inflammation | |
US20180170983A1 (en) | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment | |
WO2023246847A1 (fr) | Peptide bloquant b2m-glun1, composition pharmaceutique et son utilisation | |
JP2007284351A (ja) | アミロイド蛋白質の凝集を抑制する物質とその作用 | |
JP4447783B2 (ja) | 新規なぺプチド類 | |
JP7437855B2 (ja) | 遺伝性シスタチンcアミロイド血管症(hccaa)および異常なアミロイド沈着を伴う他の神経変性障害の治療のための組成物および方法 | |
WO2022262624A1 (fr) | UTILISATION PHARMACEUTIQUE DE β2-MICROGLOBULINE OU D'UN INHIBITEUR DE CELLE-CI | |
CN106659911B (zh) | 治疗或预防神经退行性病症的组合物和方法 | |
WO2018237383A1 (fr) | Procédés de prévention et de traitement de maladies caractérisées par un dysfonctionnement synaptique et une neurodégénérescence, y compris la maladie d'alzheimer | |
US6930169B2 (en) | Method of controlling the binding of calmyrin to presenilin | |
Mich et al. | AAV-mediated interneuron-specific gene replacement for Dravet syndrome | |
JP2022531296A (ja) | Tert活性化療法を伴う方法および組成物 | |
WO2023232083A1 (fr) | Peptide bloquant la bêta 2-microglobuline, composition pharmaceutique et utilisation associée | |
US8404806B2 (en) | Isolated BRCA1 peptides and method of use | |
AU2002363524B2 (en) | Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof | |
EP2783696B1 (fr) | Phosphorylation dans les résidus thr-248 et/ou thr-250 du facteur de transcription e2f4 en tant que cible thérapeutique dans des processus pathologiques qui débouchent sur une polyploïde somatique | |
KR20180023870A (ko) | Arl6ip1의 유전성 강직성 하반신마비의 치료 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23826492 Country of ref document: EP Kind code of ref document: A1 |